Abstract
At the intersection between treatment and diagnosis, nanoparticles technologies are strongly impacting the development of both therapeutic and diagnostic agents. Consequently, the development of novel modalities for concomitant noninvasive therapy and diagnostics known as theranostics as a single platform has gained significant interests. These multifunctional theranostic platforms include carbon-based nanomaterials (e.g., carbon nanotubes), drug conjugates, aliphatic polymers, micelles, vesicles, core-shell nanoparticles, microbubbles and dendrimers bearing different contrast agents and drugs, such as cytotoxic compounds in the oncology domain. Dendrimers emerged as a new class of highly tunable hyperbranched polymers, and have been developed as useful theranostic platforms. Magnetic resonance imaging, gamma scintigraphy, computed tomography and optical imaging are the main techniques developed with dendrimers in the theranostic domain in oncology. Different imaging agents have been used such as Gd(III), 19F, Fe2O3 (MRI), 76Br (PET), 111In, 88Y, 153Gd, 188Re, 131I (SPECT), 177Lu, gold (CT) and boronated groups, siliconnaphthalocyanines, dialkylcarbocyanines and QDs (optical imaging dyes).
摘要
纳米粒子技术作为癌症诊断和治疗的交叉点, 极大地影响着抗肿瘤药物与肿瘤诊断剂的发展. 新型无创诊疗一体化纳米平台的发 展也因此得到了人们的广泛关注. 这些多功能的诊疗一体化平台包括: 碳基纳米材料例如碳纳米管、药物缀合物、脂肪族聚合物、胶 束、囊泡、核-壳结构的纳米颗粒、微泡和负载不同造影剂和药物如肿瘤学领域中的化疗药物的树状大分子等. 树状大分子作为一类新 型高度可调控的超支化聚合物, 现已被开发出多种用于肿瘤诊疗一体化的纳米平台. 磁共振成像、γ闪烁扫描技术、计算机断层扫描和光 学成像等也成为通过树状大分子发展起来的核心技术用于肿瘤的诊疗. 不同的造影剂体系包括Gd(III)、19F, Fe2O3 (MRI)、 76Br (PET)、 111In、 88Y、 153Gd、 188Re、 131I(SPECT)、 177Lu、金纳米颗粒(CT)和硼化基团、硅萘酞菁、二烷基羰花青和量子点光学成像染料等也已经 被开发使用.
Article PDF
Similar content being viewed by others
References
Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer, 2005, 5: 161–171
Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov, 2005, 4: 145–160
Malam Y, Loizidou M, Seifalian AM. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacological Sci, 2009, 30: 592–599
Kakkar A, Traverso G, Farokhzad OC, et al. Evolution of macromolecular complexity in drug delivery systems. Nat Rev Chem, 2017, 1: 0063
Baig, T, Nayak J, Dwivedi V, et al. A review about dendrimers: Synthesis, types, characterization and applications. IJAPBC, 2015, 4: 44–59
Astruc D, Boisselier E, Ornelas C. Dendrimers designed for functions: from physical, photophysical, and supramolecular properties to applications in sensing, catalysis, molecular electronics, photonics, and nanomedicine. Chem Rev, 2010, 110: 1857–1959
Vogtle F, Richard G, Werner N. Chapter 4. Types of dendrimers and their synthesis. In: Dendrimer Chemistry: Concepts, Syntheses, Properties, Applications, Wiley-VCH Verlag, 2009
Rupp R, Rosenthal, SL, Stanberry LR. VivaGel™ (SPL7013 Gel): a candidate dendrimer-microbicide for the prevention of HIV and HSV infection. Int J Nanomedicine, 2007, 2: 561–566
Starpharma, Available at http://www.starpharma.com
Janib SM, Moses AS, MacKay JA. Imaging and drug delivery using theranostic nanoparticles. Adv Drug Deliver Rev, 2010, 62: 1052–1063
Ma Y, Mou Q, Wang D, et al. Dendritic polymers for theranostics. Theranostics, 2016, 6: 930–947
Liu Y, Zhang N. Gadolinium loaded nanoparticles in theranostic magnetic resonance imaging. Biomaterials, 2012, 33: 5363–5375
Nottelet B, Darcos V, Coudane J. Aliphatic polyesters for medical imaging and theranostic applications. Eur J Pharm Biopharm, 2015, 97: 350–370
McMahon MT, Bulte JWM. Two decades of dendrimers as versatile MRI agents: a tale with and without metals. WIREs Nanomed Nanobiotechnol, 2017, 2: e1496
Dhar S, Liu Z, Thomale J, et al. Targeted single-wall carbon nanotube-mediated Pt(IV) prodrug delivery using folate as a homing device. J Am Chem Soc, 2008, 130: 11467–11476
Pike DB, Ghandehari H. HPMA copolymer–cyclic RGD conjugates for tumor targeting. Adv Drug Deliver Rev, 2010, 62: 167–183
Gao X, Luo Y, Wang Y, et al. Prostate stem cell antigen-targeted nanoparticles with dual functional properties: in vivo imaging and cancer chemotherapy. IJN, 2012, 7: 4037–4051
Talelli M, Rijcken CJF, van Nostrum CF, et al. Micelles based on HPMA copolymers. Adv Drug Deliver Rev, 2010, 62: 231–239
Christian DA, Cai S, Bowen DM, et al. Polymersome carriers: From self-assembly to siRNA and protein therapeutics. Eur J Pharm Biopharm, 2009, 71: 463–474
Shubayev VI, Pisanic Ii TR, Jin S. Magnetic nanoparticles for theragnostics. Adv Drug Deliver Rev, 2009, 61: 467–477
Gao Z, Kennedy AM, Christensen DA, et al. Drug-loaded nano/microbubbles for combining ultrasonography and targeted chemotherapy. Ultrasonics, 2008, 48: 260–270
Thomas TP, Shukla R, Kotlyar A, et al. Dendrimer-based tumor cell targeting of fibroblast growth factor-1. Bioorg Medicinal Chem Lett, 2010, 20: 700–703
Ki Choi S, Thomas T, Li MH, et al. Light-controlled release of caged doxorubicin from folate receptor-targeting PAMAM dendrimer nanoconjugate. Chem Commun, 2010, 46: 2632–2634
Singh P, Gupta U, Asthana A, et al. Folate and Folate−PEG−PAMAM dendrimers: synthesis, characterization, and targeted anticancer drug delivery potential in tumor bearing mice. Bioconjugate Chem, 2008, 19: 2239–2252
Zhao Y, Liu S, Li Y, et al. Synthesis and grafting of folate–PEG–PAMAM conjugates onto quantum dots for selective targeting of folate-receptor-positive tumor cells. J Colloid Interface Sci, 2010, 350: 44–50
Li Y, Li Y, Zhang X, et al. Supramolecular PEGylated dendritic systems as pH/redox dual-responsive theranostic nanoplatforms for platinum drug delivery and NIR imaging. Theranostics, 2016, 6: 1293–1305
Wiener E, Brechbiel MW, Brothers H, et al. Dendrimer-based metal chelates: A new class of magnetic resonance imaging contrast agents. Magn Reson Med, 1994, 31: 1–8
Zhu J, Gale EM, Atanasova I, et al. Hexameric MnII dendrimer as MRI contrast agent. Chem Eur J, 2014, 20: 14507–14513
Aime S, Caravan P. Biodistribution of gadolinium-based contrast agents, including gadolinium deposition. J Magn Reson Imag, 2009, 30: 1259–1267
Kanal E, Tweedle MF. Residual or retained gadolinium: practical implications for radiologists and our patients. Radiology, 2015, 275: 630–634
Aime S, Barge A, Delli Castelli D, et al. Paramagnetic Lanthanide (III) complexes as pH-sensitive chemical exchange saturation transfer (CEST) contrast agents for MRI applications. Magn Reson Med, 2002, 47: 639–648
Zhang S, Winter P, Wu K, et al. A novel europium(III)-based MRI contrast agent. J Am Chem Soc, 2001, 123: 1517–1518
Ruiz-Cabello J, Barnett BP, Bottomley PA, et al. Fluorine (19F) MRS and MRI in biomedicine. NMR Biomed, 2011, 24: 114–129
Xu R, Wang Y, Wang X, et al. In vivo evaluation of a PAMAMcystamine-( Gd-DO3A) conjugate as a biodegradable macromolecular MRI contrast agent. Exp Biol Med (Maywood), 2007, 232: 1081–1089
Klemm PJ, Floyd Iii WC, Smiles DE, et al. Improving T1 and T2 magnetic resonance imaging contrast agents through the conjugation of an esteramide dendrimer to high-water-coordination Gd(III) hydroxypyridinone complexes. Contrast Media Mol Imag, 2012, 7: 95–99
Ye M, Qian Y, Shen Y, et al. Facile synthesis and in vivo evaluation of biodegradable dendritic MRI contrast agents. J Mater Chem, 2012, 22: 14369–14377
Ye M, Qian Y, Tang J, et al. Targeted biodegradable dendritic MRI contrast agent for enhanced tumor imaging. J Control Release, 2013, 169: 239–245
Li T, Qian Y, Ye M, et al. Synthesis and properties of a biodegradable dendritic magnetic resonance imaging contrast agent. Chin J Chem, 2014, 32: 91–96
Konda SD, Aref M, Wang S, et al. Specific targeting of folatedendrimer MRI contrast agents to the high affinity folate receptor expressed in ovarian tumor xenografts. Magna, 2001, 12: 104–113
Mohs AM, Lu ZR. Gadolinium(III)-based blood-pool contrast agents for magnetic resonance imaging: status and clinical potential. Expert Opin Drug Deliver, 2007, 4: 149–164
Kaneshiro TL, Jeong EK, Morrell G, et al. Synthesis and evaluation of globular Gd-DOTA-monoamide conjugates with precisely controlled nanosizes for magnetic resonance angiography. Biomacromolecules, 2008, 9: 2742–2748
Cyran CC, Fu Y, Raatschen HJ, et al. New macromolecular polymeric MRI contrast agents for application in the differentiation of cancer from benign soft tissues. J Magn Reson Imag, 2008, 27: 581–589
Filippi M, Catanzaro V, Patrucco D, et al. First in vivo MRI study on theranostic dendrimersomes. J Control Release, 2017, 248: 45–52
Criscione JM, Le BL, Stern E, et al. Self-assembly of pH-responsive fluorinated dendrimer-based particulates for drug delivery and noninvasive imaging. Biomaterials, 2009, 30: 3946–3955
Luong D, Sau S, Kesharwani P, et al. Polyvalent folate-dendrimercoated iron oxide theranostic nanoparticles for simultaneous magnetic resonance imaging and precise cancer cell targeting. Biomacromolecules, 2017, 18: 1197–1209
Almutairi A, Rossin R, Shokeen M, et al. Biodegradable dendritic positron-emitting nanoprobes for the noninvasive imaging of angiogenesis. Proc Natl Acad Sci USA, 2009, 106: 685–690
Dijkgraaf I, Rijnders AY, Soede A, et al. Synthesis of DOTAconjugated multivalent cyclic-RGD peptide dendrimers via 1,3-dipolar cycloaddition and their biological evaluation: implications for tumor targeting and tumor imaging purposes. Org Biomol Chem, 2007, 5: 935–944
Kobayashi H, Sato N, Saga T, et al. Monoclonal antibody-dendrimer conjugates enable radiolabeling of antibody with markedly high specific activity with minimal loss of immunoreactivity. Eur J Nucl Med, 2000, 27: 1334–1339
Kobayashi H, Wu C, Kim MK, et al. Evaluation of the in vivo biodistribution of indium-111 and yttrium-88 labeled dendrimer-1B4M-DTPA and its conjugation with anti-tac monoclonal antibody. Bioconjugate Chem, 1999, 10: 103–111
Li N, Jin Y, Xue LZ, et al. 188Re-Labeled hyperbranched polysulfonamine as a robust tool for targeted cancer diagnosis and radioimmunotherapy. Chin J Polym Sci, 2013, 3: 530–540
Zhu J, Zhao L, Cheng Y, et al. Radionuclide 131I-labeled multifunctional dendrimers for targeted SPECT imaging and radiotherapy of tumors. Nanoscale, 2015, 7: 18169–18178
Zhao L, Zhu J, Cheng Y, et al. Chlorotoxin-conjugated multifunctional dendrimers labeled with radionuclide 131I for single photon emission computed tomography imaging and radiotherapy of gliomas. ACS Appl Mater Interfaces, 2015, 7: 19798–19808
Grünwald GK, Vetter A, Klutz K, et al. Systemic image-guided liver cancer radiovirotherapy using dendrimer-coated adenovirus encoding the sodium iodide symporter as theranostic gene. J Nucl Med, 2013, 54: 1450–1457
Yordanov AT, Lodder AL, Woller EK, et al. Novel iodinated dendritic nanoparticles for computed tomography (CT) imaging. Nano Lett, 2002, 2: 595–599
Mendoza-Nava H, Ferro-Flores G, Ramírez FM, et al. 177Lu-dendrimer conjugated to folate and bombesin with gold nanoparticles in the dendritic cavity: a potential theranostic radiopharmaceutical. J Nanomaterials, 2016, 2016: 1–11
Guo R, Shi X. Dendrimers in cancer therapeutics and diagnosis. CDM, 2012, 13: 1097–1109
Li D, Wen S, Shi X. Dendrimer-entrapped metal colloids as imaging agents. WIREs Nanomed Nanobiotechnol, 2015, 7: 678–690
Qiao Z, Shi X. Dendrimer-based molecular imaging contrast agents. Prog Polymer Sci, 2015, 44: 1–27
Peng C, Wang H, Guo R, et al. Acetylation of dendrimer-entrapped gold nanoparticles: Synthesis, stability, and X-ray attenuation properties. J Appl Polym Sci, 2011, 119: 1673–1682
Wang H, Zheng L, Peng C, et al. Computed tomography imaging of cancer cells using acetylated dendrimer-entrapped gold nanoparticles. Biomaterials, 2011, 32: 2979–2988
Wang H, Zheng L, Peng C, et al. Folic acid-modified dendrimerentrapped gold nanoparticles as nanoprobes for targeted CT imaging of human lung adencarcinoma. Biomaterials, 2013, 34: 470–480
Vinegoni C, Feruglio PF, Cortez-Retamozo V, et al. Imaging of molecular probe activity with Born-normalized fluorescence optical projection tomography. Opt Lett, 2010, 35: 1088–1090
Guo R, Li R, Li X, et al. Dual-functional alginic acid hybrid nanospheres for cell imaging and drug delivery. Small, 2009, 5: 709–717
Connor EE, Mwamuka J, Gole A, et al. Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. Small, 2005, 1: 325–327
Peng C, Zheng L, Chen Q, et al. PEGylated dendrimer-entrapped gold nanoparticles for in vivo blood pool and tumor imaging by computed tomography. Biomaterials, 2012y, 33: 1107–1119
Peng C, Qin J, Zhou B, et al. Targeted tumor CT imaging using folic acid-modified PEGylated dendrimer-entrapped gold nanoparticles. Polym Chem, 2013, 4: 4412–4424
Liu H, Wang H, Xu Y, et al. Lactobionic acid-modified dendrimerentrapped gold nanoparticles for targeted computed tomography imaging of human hepatocellular carcinoma. ACS Appl Mater Interfaces, 2014, 6: 6944–6953
Cao Y, He Y, Liu H, et al. Targeted CT imaging of human hepatocellular carcinoma using low-generation dendrimer-entrapped gold nanoparticles modified with lactobionic acid. J Mater Chem B, 2015, 3: 286–295
Liu H, Wang H, Xu Y, et al. Synthesis of PEGylated low generation dendrimer-entrapped gold nanoparticles for CT imaging applications. Nanoscale, 2014, 6: 4521–4526
Liu H, Xu Y, Wen S, et al. Facile hydrothermal synthesis of low generation dendrimer-stabilized gold nanoparticles for in vivo computed tomography imaging applications. Polym Chem, 2013, 4: 1788–1795
Liu H, Xu Y, Wen S, et al. Targeted tumor computed tomography imaging using low-generation dendrimer-stabilized gold nanoparticles. Chem Eur J, 2013, 19: 6409–6416
Guo R, Wang H, Peng C, et al. Enhanced X-ray attenuation property of dendrimer-entrapped gold nanoparticles complexed with diatrizoic acid. J Mater Chem, 2011, 21: 5120–5127
Peng C, Li K, Cao X, et al. Facile formation of dendrimer-stabilized gold nanoparticles modified with diatrizoic acid for enhanced computed tomography imaging applications. Nanoscale, 2012, 4: 6768–6778
Backer MV, Gaynutdinov TI, Patel V, et al. Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature. Mol Cancer Ther, 2005, 4: 1423–1429
Nguyen QT, Olson ES, Aguilera TA, et al. Surgery with molecular fluorescence imaging using activatable cell-penetrating peptides decreases residual cancer and improves survival. Proc Natl Acad Sci USA, 2010, 107: 4317–4322
Taratula O, Schumann C, Duong T, et al. Dendrimer-encapsulated naphthalocyanine as a single agent-based theranostic nanoplatform for near-infrared fluorescence imaging and combinatorial anticancer phototherapy. Nanoscale, 2015, 7: 3888–3902
Taratula O, Schumann C, Naleway MA, et al. A multifunctional theranostic platform based on phthalocyanine-loaded dendrimer for image-guided drug delivery and photodynamic therapy. Mol Pharm, 2013, 10: 3946–3958
Morales-Cruz M, Figueroa CM, González-Robles T, et al. Activation of caspase-dependent apoptosis by intracellular delivery of cytochrome c-based nanoparticles. J Nanobiotechnol, 2014, 12: 1–11
Santra S, Kaittanis C, Perez JM. Cytochrome c encapsulating theranostic nanoparticles: a novel bifunctional system for targeted delivery of therapeutic membrane-impermeable proteins to tumors and imaging of cancer therapy. Mol Pharm, 2010, 7: 1209–1222
Caminade AM, Hameau AÃ, Majoral JP. Multicharged and/or water-soluble fluorescent dendrimers: properties and uses. Chem Eur J, 2009, 15: 9270–9285
Griffe L, Poupot M, Marchand P, et al. Multiplication of human natural killer cells by nanosized phosphonate-capped dendrimers. Angew Chem Int Ed, 2007, 46: 2523–2526
Poupot M, Griffe L, Marchand P, et al. Design of phosphorylated dendritic architectures to promote human monocyte activation. FASEB J, 2006, 20: 2339–2351
Hayder M, Poupot M, Baron M, et al. A phosphorus-based dendrimer targets inflammation and osteoclastogenesis in experimental arthritis. Sci Translational Med, 2011, 3: 81ra35–81ra35
Caminade AM, Fruchon S, Turrin CO, et al. The key role of the scaffold on the efficiency of dendrimer nanodrugs. Nat Commun, 2015, 6: 7722
Poupot M, Turrin CO, Caminade AM, et al. Poly(phosphorhydrazone) dendrimers: yin and yang of monocyte activation for human NK cell amplification applied to immunotherapy against multiple myeloma. NanoMed-Nanotechnol Biol Med, 2016, 12: 2321–2330
El Brahmi N, El Kazzouli S, Mignani SM, et al. Original multivalent copper(II)-conjugated phosphorus dendrimers and corresponding mononuclear copper(II) complexes with antitumoral activities. Mol Pharm, 2013, 10: 1459–1464
Mignani S, El Brahmi N, Eloy L, et al. Anticancer copper(II) phosphorus dendrimers are potent proapoptotic Bax activators. Eur J Medicinal Chem, 2017, 132: 142–156
Wei P, Chen J, Hu Y, et al. Dendrimer-stabilized gold nanostars as a multifunctional theranostic nanoplatform for CT imaging, photothermal therapy, and gene silencing of tumors. Adv Healthcare Mater, 2016, 5: 3203–3213
Kong L, Xing L, Zhou B, et al. Dendrimer-modified MoS2 nanoflakes as a platform for combinational gene silencing and photothermal therapy of tumors. ACS Appl Mater Interfaces, 2017, 9: 15995–16005
Vargas JG. Dendrimers: from the art of building precise molecules to the dissemination through the world. Braz J Pharm Sci, 2013, 49: 4–5
Kalhapure RS, Kathiravan MK, Akamanchi KG, et al. Dendrimers —from organic synthesis to pharmaceutical applications: an update. Pharmaceutical Dev Tech, 2015, 20: 22–40
Mignani S, Rodrigues J, Tomas H, et al. Bench-to-bedside translation of dendrimers: Reality or utopia? A concise analysis. Adv Drug Deliver Rev, 2017, 10.1016/j.addr.2017.11.007
Mignani S, Kazzouli SE, Bousmina M, et al. Dendrimer space concept for innovative nanomedicine: A futuristic vision for medicinal chemistry. Prog Polymer Sci, 2013, 38: 993–1008
Leiro V, Garcia JP, Tomás H, et al. The present and the future of degradable dendrimers and derivatives in theranostics. Bioconjugate Chem, 2015, 26: 1182–1197
Alberto RFR, Joao R, de Los Angeles MFM, et al. Principal physicochemical methods used to characterize dendrimer molecule complexes used as genetic therapy agents, nanovaccines or drug carriers. CPD, 2017, 23
Patel SK, Janjic JM. Macrophage targeted theranostics as personalized nanomedicine strategies for inflammatory diseases. Theranostics, 2015, 5: 150–172
Acknowledgements
This review is the result of intense cooperation between France, China and Portugal in the domain of dendrimers and cannot be possible without the devotion of our coworkers, the work of the colleagues all over the world and the support of several funding agencies. Mignani S, Rodrigues J, and Tomas H acknowledge the support of FCT-Fundação para a Ciência e a Tecnologia (project PEst-OE/ QUI/UI0674/2013, CQM, Portuguese Government funds), and ARDITI through the project M1420-01-0145-FEDER-000005 - Centro de Química da Madeira - CQM+ (Madeira 14-20), and Majoral J-P also acknowledges the funds from Centre National de la Recherche Scientifique (CNRS, France). Shi X acknowledges the support by the National Natural Science Foundation of China (21773026 and 81761148028), and (Mignani S, Majoral J-P and Shi X) by the Sino-French Caiyuanpei Programme.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Serge Mignani was Head of the Medicinal Chemistry Department and Scientific Director (Sanofi). In 2017, he was nominated as Professor in medicinal chemistry at the Centro de Quimica da Madeira, University of Madeira at Fungal, Portugal. He is member of scientific advisory board of Glycovax Pharma (Montreal, Canada), and Sai Phytoceuticals (New Delhi, India). He is consultant in medicinal chemistry at the Indian Institute of Integrative Medicine (Prof. R. Vishwakarma, IIIM, Jammu, India), the ‘Laboratoire Chimie de Coordination’ (Prof. J-P. Majoral, Toulouse, France), and the Donghua University (Prof. X. Shi, Shanghai, China).
Joao Rodrigues is a staff member of the University of Madeira since 1999 (Portugal) and Adjunct Professor at Northwestern Polytechnical University, Xi’an (China) since June 2017. In September 2017, he was nominated member of the Scientific Board of the Portuguese National Science Foundation (FCT) in the areas of Exact Sciences and Engineering. In the last three years, he authored 24 papers and 2 book chapters (h index 21, i10 index = 30). His main research interests are on the synthesis and characterization of molecular materials namely, nanoparticles, dendrimers and polymers for biomedical applications (e.g., emergent and infectious diseases, and oncology).
Xiangyang Shi obtained his PhD degree in 1998 from the Chinese Academy of Sciences. From 2002–2008, he was appointed as a research fellow, research associate II, research investigator, and research assistant professor in Michigan Nanotechnology Institute for Medicine and Biological Sciences, University of Michigan, Ann Arbor. In September 2008, he joined Donghua University as a full professor. He has published more than 268 peer-reviewed SCI-indexed journal articles. His current research interests are focused on dendrimer-based nanomedicine, and electrospun polymer nanofiber- based technology for applications in regenerative medicine, sensing, and therapeutics.
Rights and permissions
About this article
Cite this article
Mignani, S., Rodrigues, J., Tomas, H. et al. Recent therapeutic applications of the theranostic principle with dendrimers in oncology. Sci. China Mater. 61, 1367–1386 (2018). https://doi.org/10.1007/s40843-018-9244-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40843-018-9244-5